Semi-quantitative assessment of salivary gland function in patients with differentiated thyroid carcinoma after radioiodine-131 treatment

Hellenic Journal of Nuclear Medicine

Volumn 7, Issue 3, 2004, Pages 206-209

  Esfahani, Armaghan Fard ^a   Fallahi, Babak ^a   Olamaie, Reza ^a   Eftekhari, Mohammad ^a   Beiki, Davood ^a   Saghari, Mohssen ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Differentiated thyroid carcinoma; Radioiodine treatment; Salivary gland function; Scintigraphy of salivary glands

Indexed keywords

IODINE 131; PERTECHNETIC ACID TC 99M;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; PAROTID GLAND; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RADIOSENSITIVITY; SALIVARY GLAND DISEASE; SALIVARY GLAND SCINTISCANNING; SALIVATION; SIALOADENITIS; SUBMANDIBULAR GLAND; THYROID CARCINOMA; TREATMENT OUTCOME; XEROSTOMIA;

EID: 13244271372     PISSN: 00258024     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Silberstein EB. The treatment of thyroid malignancies. In: Henkin RE, Boles MA, Karesh SM, et al. Nuclear medicine, New York: Mosby, 1996: 1557-1565.
2. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med 2002; 27: 767-771.
3. Shirazi P. Salivary glands. In: Henkin RE, Boles MA, Karesh SM, et al. Nuclear medicine, New York: Mosby, 1996: 933-947.
4. Wolfram RM, Budinsky AC, Palumbo B, et al. Radioiodine therapy induces dose-dependent in vivo oxidation injury: evidence by increased isoprostane 8-epi-PGF (2 alpha). J Nucl Med 2002; 43: 1254-1258.
5. Baum BJ, Fox PC, Neuman RD. The salivary glands. In: Harbert JC, Eckelman WC, Neumann RD. Nuclear Medicine: diagnosis and therapy New York, USA Thieme Medical Publishers, 1996: 439-444.
6. Calcagni ML, Giuda DD, Rossi GD. Salivary gland disorders In: Murray IPC, Ell PJ. Nuclear medicine in clinical diagnosis and treatment. Edinburgh, UK. Churhill Livingstone, 2nd edition, 1998: 399-402.
7. Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiot Oncol Biol Phys 1996; 35: 535-540.
8. Tsujii H. Quantitative dose-response analysis of salivary function following radiotherapy using sequentional RI-sialography. Int J Radiot Oncol Biol Phys 1985; 11: 1603-1612.
9. Olmos RAV, Keus RB, Takes RP. Scintigraphic assessment of salivary gland function and excretion response in radiation-induced injury of the major salivary glands. Cancer 1994; 73: 2886-2893.
10. Cooper JS, Fu K, Marks J, et al. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys 1995; 31: 1141-1164.
11. Albrecht HH, Creutzig H. Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy ROFO Fortschr Geb Rontgenstr Nuklearmed 1976; 125: 546-551.
12. Solans R, Bosch JA, Galofre P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001; 42: 738-743.